29 apr: HVIDT I HVIDT - 20 COOL DESIGNKØB
05 maj: FORÅRS (MAVE) FORNEMMELSE - FEM FANTASTISKE OPSKRIFTER
04-05-2011 07:30:26

First Quarter of 2011: Dräger increases net sales and earnings

Drägerwerk AG & Co. KGaA /

First Quarter of 2011: Dräger increases net sales and earnings

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

  • Earnings after income taxes grew 24 percent year-on-year
  • Growth forecast confirmed
  • Stefan Dräger: "Capital structure increases strategic scope of action"

Lübeck - Drägerwerk AG & Co. KGaA's order intake, net sales and earnings increased in the first quarter of 2011. Order intake went up by 11.8 percent (net of currency effects) to EUR 553.6 million year-on-year. Net sales rose by 5.7 percent (net of currency effects) to EUR 500.3 million, with particularly positive developments in the Americas and Asia / Pacific regions. The safety division recorded 9.1 percent growth (net of currency effects), net sales in the medical divisions increased by 3.7 percent. "Given the good first quarter, we are confirming our 2011 growth forecast," said Stefan Dräger, CEO of Drägerwerk Verwaltungs AG.

EBIT margin rose to 8.5 percent

Dräger achieved total Group EBIT of EUR 42.6 million in the first quarter of 2011, an increase of 15.9 percent compared to the prior year's period. The EBIT margin rose from 7.9 percent to 8.5 percent. Higher net sales, favorable exchange rates and positive changes to the product mix contributed to the development. As planned, these amounts were partially used as increased expenses for research and development, marketing and sales as well as IT infrastructure. Earnings after income taxes rose by 24 percent to EUR 23.2 million year-on-year.

Equity ratio went up to 33.1 percent

Dräger Group's equity rose by EUR 11.2 million to EUR 647.8 million in the first three months of 2011, with the equity ratio increasing from 32.2 percent on December 31, 2010, to 33.1 percent. On March 31, 2010, prior to the capital increase, the equity ratio had been at 21.8 percent. "We have more strategic scope of action as our equity is increasing. For this reason, we are aiming to generate an equity ratio of at least 35 percent. We want to be ready for the next slump of the global economy," highlighted Stefan Dräger.

Outlook: Order intake is expected to grow as fast as the overall global economy

Dräger expects its order intake in fiscal year 2011 to grow at least at the pace of global economic growth (IMF April 2011 forecast: +4.4 percent). This is based on the assumption of a stabilizing economy in Europe, continued economic recovery in North America, sustained market growth in developing countries and stable exchange rates. Lifecycle Solutions and Infrastructure Projects in particular are likely to drive expected growth in the lower one-digit percentage range in the medical division and compensate for a possible slowdown in the equipment business. Dräger expects increases in net sales for the safety division in the medium one-digit percentage range. According to the Executive Board, net sales growth in the Group in 2011 is expected to be one to two percentage points down on order intake growth as net sales in 2010 benefited from above-average order intake in the fourth quarter of 2009. Based on planned increases in product development investments, the expansion of the sales organization and improvements to the Group-wide IT infrastructure, Dräger still expects a Group EBIT margin between 7.5 percent and 8.5 percent for fiscal year 2011 (2010: 8.9 percent). In the medium term, the Company aims at growing stronger than the market and achieving an EBIT margin of at least 10 percent.

Key figures for the first three months of 2011 (€ million)

  Q1 2011 Q1 2010 Change Net of currency effects
Order intake 553.6 488.2 +13.4% +11.8%

Medical division

357.1

323.6

+10.4%

+9.2%

Safety division

204.0

172.3

+18.4%

+16.1%

         
Net sales 500.3 465.9 +7.4% +5.7%

Medical division

321.6

306.3

+5.0%

+3.7%

Safety division

185.9

167.0

+11.3%

+9.1%

         
EBIT[1] 42.6 36.8 +15.9%  

Medical division

30.6

40.3

-24.1%

 

Safety division

21.6

12.7

+69.7%

 

         
EBIT margin 8.5% 7.9%    
Earnings after income taxes 23.2 18.7    
EPS[2] preferred share 1.22 1.38    
EPS[2] common share 1.20 1.36    

 

[1] EBIT = Earnings before interest and taxes
[2] EPS = Earnings per share (in €)

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

 

Contact

Corporate Communications:

Burkard Dillig

Phone: +49 451 882-2185

burkard.dillig@draeger.com

Investor Relations:

Vanina Hoffmann

Phone: +49 451 882-2685

vanina.hoffmann@draeger.com

Drägerwerk AG & Co. KgaA

Moislinger Allee 53-55

23558 Lübeck, Germany

www.draeger.com

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1512151

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 jul
TOPO
Kurshop -  Der findes tusinder af Biotekfirmaer i verden som du kan gå ud og investerer i ! Hvad er ..
17
23 jul
VWS
Jeg sidder og graver mig ind i dette lille interessante skriv:   http://www.power-technology.com/new..
15
20 jul
VELO
Sidder ig gennemlaser tidligere traade og samler her lidt op og vil komme med betragtninger for den ..
13
24 jul
OMXN40
Det bliver/er hverdagskost i alle europæiske lande inden længe.. Men tankevækkende, at terrortruslen..
12
25 jul
EXQ
Så lykkedes det at komme til Vedbæk for at besøge Exiqon. Damen, en kammerat og jeg selv blev taget ..
11
23 jul
PNDORA
Det er helt naturligt, at aktiekursen på et selskab, som er steget meget, svinger kraftigt forud for..
10
22 jul
VWS
Mon dette forum og skribenterne mon nogensinde bliver så voksent, at vi er undgår dette evindelige b..
8
21 jul
E:VWS
Du kan da umuligt fjerne kernemedarbejdere med 10-30 års erfaring når de ikke engang har haft fabrik..
8
25 jul
VELO
@ Jennis69. Indtægter. De havede indtægter på 38 mill. sidste år. Såvidt jeg kan se, er der en mil..
7
19 jul
I:SP500
  Uden selv at tage den gl. tyske kansler til indtægt for synspunktet, kunne det vække til eftertank..
7

Danske Bank: Nye kursmål og anbefalinger efter regnskab - NY2

25-07-2014 15:31:22
En lang række analysehuse har opjusteret kursmålet på Danske Bank efter regnskabet for andet kvartal torsdag.De fleste lægger mellem 5 og 10 kr. til kursmålet f..

Novo Nordisk/analytikere: Europæisk anbefaling vigtigt kryds

25-07-2014 14:07:38
En lægemiddelkomite under den europæiske sundhedsmyndighed, EMA, har anbefalet Novo Nordisks kombinationsprodukt Ideglira. Mens det er positivt, og et vigtigt k..

Aktier/middag: Vestas blæser C20 i plus

25-07-2014 11:37:02
Efter en underdrejet start har det danske aktiemarked igen fundet sine "gode ben" fredag formiddag, hvor der er en let fremgang at spore. Tunge aktier som Vesta..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank: Kurs- og anbefalingsændringer efter regnskabet
2
Luksusaktie straffes efter skidt regnskab
3
Genmab: Amerikansk børshus vender tilbage med købsanbefaling
4
Aktier/middag: Vestas blæser C20 i plus
5
Banker/ABM: Større potentiale i Sydbank og Jyske end i Danske
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. juli 2014 01:03:29
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140723.1 - EUROWEB6 - 2014-07-26 01:03:29 - 2014-07-26 01:03:29 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x